Persistent Sex Disparities in Invasive Pneumococcal Diseases in the Conjugate Vaccine Era.

BACKGROUND Few studies have characterized the role of sex on the incidence of invasive pneumococcal disease (IPD). We examined sex differences in rates of IPD, and trends after the introduction of pneumococcal conjugate vaccines (PCVs). METHODS We used active population and laboratory-based IPD surveillance data from the Centers for Disease Control and Prevention Active Bacterial Core surveillance program (1998-2013) in Tennessee. Population-based rates of IPD by sex, race, age group, and PCV era were calculated. Rates were compared using incidence rate ratios. RESULTS Throughout the study years, rates of IPD were higher in male than in female subjects, particularly in children <2 years and adults 40-64 years of age, with male subjects having IPD rates 1.5-2 times higher than female subjects. The proportions of comorbid conditions were similar in male and female subjects . Sex rate differences persisted after stratification by race. Although the introductions of 7-valent PCV (PCV7) and 13-valent PCV (PCV13) were associated with declines in IPD rates in both sexes, rates of IPD after PCV13 were still significantly higher in male than in female subjects among children and adults 40-64 and >74 years of age. CONCLUSIONS Rates of IPD were generally higher in male than in female subjects. These sex differences were observed in different race groups and persisted after introduction of both PCVs.

[1]  W. Schaffner,et al.  Racial and Regional Differences in Rates of Invasive Pneumococcal Disease , 2015, Pediatrics.

[2]  M. G. Bupp Sex, the aging immune system, and chronic disease. , 2015 .

[3]  W. Schaffner,et al.  Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. , 2015, The Lancet. Infectious diseases.

[4]  M. Altfeld,et al.  Sex differences in infectious diseases-common but neglected. , 2014, The Journal of infectious diseases.

[5]  P. Goulder,et al.  Sex Differences in Pediatric Infectious Diseases , 2014, The Journal of infectious diseases.

[6]  Á. Gentile [U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination]. , 2014, Archivos argentinos de pediatria.

[7]  S. Pelton,et al.  Risk of pneumococcal disease in children with chronic medical conditions in the era of pneumococcal conjugate vaccine. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  W. Schaffner,et al.  Racial disparities in invasive Streptococcus pneumoniae infections, 1998-2009. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  S. Kaplan,et al.  Early Trends for Invasive Pneumococcal Infections in Children After the Introduction of the 13-valent Pneumococcal Conjugate Vaccine , 2013, The Pediatric infectious disease journal.

[10]  T. Lieu,et al.  Healthcare utilization and cost of pneumococcal disease in the United States. , 2011, Vaccine.

[11]  C. Whitney,et al.  Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2010, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[12]  W. Schaffner,et al.  Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. , 2010, The Journal of infectious diseases.

[13]  S. Dowell,et al.  Holiday spikes in pneumococcal disease among older adults. , 2009, The New England journal of medicine.

[14]  J. Stockman Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis , 2009 .

[15]  A. Reunanen,et al.  Effects of Ageing and Gender on Naturally Acquired Antibodies to Pneumococcal Capsular Polysaccharides and Virulence-Associated Proteins , 2008, Clinical and Vaccine Immunology.

[16]  W. Schaffner,et al.  Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. , 2008, The Journal of infectious diseases.

[17]  Susan S. Huang,et al.  Emergence of 19A as Virulent and Multidrug Resistant Pneumococcus in Massachusetts Following Universal Immunization of Infants With Pneumococcal Conjugate Vaccine , 2007, The Pediatric infectious disease journal.

[18]  P. Formenty,et al.  Addressing sex and gender in epidemic-prone infectious diseases , 2007 .

[19]  W. Schaffner,et al.  Elimination of Racial Differences in Invasive Pneumococcal Disease in Young Children After Introduction of the Conjugate Pneumococcal Vaccine , 2004, The Pediatric infectious disease journal.

[20]  S. Schrag,et al.  Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections. , 2004, JAMA.

[21]  L. Harrison,et al.  Active bacterial core surveillance of the emerging infections program network. , 2001, Emerging infectious diseases.

[22]  M. Leinonen,et al.  Epidemiology of invasive Streptococcus pneumoniae infections in adults in Finland , 1997, Epidemiology and Infection.

[23]  A J Hall,et al.  Serogroup-specific epidemiology of Streptococcus pneumoniae: associations with age, sex, and geography in 7,000 episodes of invasive disease. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  M. Leinonen,et al.  Epidemiology of invasive pneumococcal infections in children in Finland. , 1992, JAMA.

[25]  R. Norrby,et al.  Invasive pneumococcal infections: incidence, predisposing factors, and prognosis. , 1985, Reviews of infectious diseases.

[26]  M. Graffar [Modern epidemiology]. , 1971, Bruxelles medical.